• LAST PRICE
    4.1900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.1500/ 17
  • Ask / Lots
    4.3500/ 2
  • Open / Previous Close
    0.0000 / 4.1900
  • Day Range
    ---
  • 52 Week Range
    Low 0.3599
    High 6.0400
  • Volume
    1,379
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 4.3
TimeVolumeADCT
09:32 ET49984.2
09:34 ET9004.36
09:36 ET1004.4
09:38 ET9004.37
09:39 ET12004.385
09:41 ET19164.4
09:43 ET13004.39
09:45 ET5004.39
09:54 ET1164.31
09:56 ET50034.295
09:57 ET1004.31
09:59 ET1004.31
10:01 ET7374.2901
10:03 ET9864.295
10:06 ET4134.28
10:08 ET47314.33
10:10 ET6004.29
10:14 ET16394.275
10:15 ET5424.27
10:17 ET5004.26
10:19 ET34164.28
10:26 ET18604.24
10:28 ET1004.25
10:30 ET72004.22
10:32 ET7004.22
10:33 ET3314.23
10:37 ET26004.22
10:39 ET4144.24
10:42 ET1174.24
10:44 ET4654.21
10:51 ET1004.21
10:53 ET2004.2
10:55 ET1004.2103
10:57 ET8154.2
11:00 ET2004.21
11:02 ET1004.2
11:06 ET1354.2005
11:08 ET8804.23
11:09 ET6434.2399
11:11 ET6004.2293
11:13 ET3334.23
11:18 ET1004.24
11:24 ET13884.26
11:29 ET1004.26
11:40 ET14264.27
11:42 ET5414.27
11:56 ET7004.29
11:58 ET28004.28
12:02 ET7474.27
12:03 ET5504.2602
12:05 ET11934.28
12:09 ET5324.27
12:12 ET4954.27
12:14 ET6004.27
12:16 ET1004.27
12:18 ET1004.2601
12:21 ET3004.27
12:25 ET10004.27
12:27 ET1334.28
12:32 ET16854.28
12:54 ET5004.2884
12:56 ET13574.3
12:57 ET1004.2988
12:59 ET1004.3
01:01 ET1004.3
01:03 ET14674.28
01:15 ET1004.275
01:17 ET6534.275
01:19 ET5204.275
01:21 ET3304.28
01:24 ET1004.28
01:28 ET2004.28
01:30 ET1004.28
01:32 ET1004.28
01:33 ET3744.27
01:37 ET1004.27
01:39 ET3004.271
01:42 ET29624.275
01:44 ET4404.28
01:48 ET2004.27
01:50 ET38964.275
01:55 ET20994.27
01:57 ET5264.26
02:02 ET1004.27
02:04 ET1004.27
02:06 ET10004.2601
02:08 ET5944.27
02:09 ET2004.27
02:13 ET19914.27
02:15 ET1004.28
02:18 ET1004.27
02:20 ET1004.27
02:22 ET1004.27
02:24 ET2004.27
02:26 ET1004.28
02:27 ET2004.27
02:29 ET16854.27
02:31 ET22514.25
02:33 ET5724.255
02:36 ET1004.25
02:38 ET15004.25
02:40 ET2004.26
02:42 ET44644.255
02:44 ET1004.255
02:45 ET1004.255
02:47 ET5004.25
02:51 ET13994.255
02:54 ET1004.255
02:58 ET17814.255
03:00 ET1004.25
03:02 ET3004.26
03:03 ET124424.235
03:05 ET2004.235
03:07 ET2004.235
03:09 ET2004.24
03:12 ET1004.24
03:14 ET2004.24
03:16 ET4004.24
03:18 ET33174.24
03:21 ET4004.24
03:23 ET1004.24
03:25 ET2004.24
03:27 ET5504.235
03:30 ET3004.24
03:32 ET2004.24
03:34 ET3004.24
03:36 ET2004.24
03:38 ET19004.235
03:39 ET6004.23
03:41 ET5004.24
03:43 ET8004.23
03:45 ET9004.235
03:48 ET45574.235
03:50 ET18924.235
03:52 ET17584.23
03:54 ET14444.235
03:56 ET37004.235
03:57 ET23614.23
03:59 ET134324.19
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADCT
ADC Therapeutics SA
403.0M
-1.5x
---
United StatesFATE
Fate Therapeutics Inc
472.3M
-2.2x
---
United StatesEDIT
Editas Medicine Inc
469.6M
-2.7x
---
United StatesCTNM
Contineum Therapeutics Inc
405.0M
17.1x
---
United StatesURGN
Urogen Pharma Ltd
472.2M
-3.9x
---
United StatesCDXS
Codexis Inc
254.7M
-3.8x
---
As of 2024-05-14

Company Information

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters
Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Ron Squarer
Chief Executive Officer, Director
Ameet Mallik
Vice Chairman of the Board
Michael Forer
Co-Founder, Non-Executive Director
Christopher Martin
Chief Financial Officer
Jose Carmona

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$403.0M
Revenue (TTM)
$68.6M
Shares Outstanding
96.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.68
EPS
$-2.77
Book Value
$-1.80
P/E Ratio
-1.5x
Price/Sales (TTM)
5.9
Price/Cash Flow (TTM)
---
Operating Margin
-216.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.